<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526419</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003258</org_study_id>
    <nct_id>NCT03526419</nct_id>
  </id_info>
  <brief_title>Exparel PK and Breast Milk Excretion</brief_title>
  <official_title>Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine After TAP Block in Patients Undergoing Cesarean Section Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the pharmacokinetics of Liposomal Bupivacaine and its excretion in breast milk in
      patients undergoing TAP block after their scheduled C -section delivery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>milk plasma ratio</measure>
    <time_frame>72 hours</time_frame>
    <description>AUC for the milk/plasma drug ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of plasma</measure>
    <time_frame>72 hours</time_frame>
    <description>AUC for drug concentration in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of milk</measure>
    <time_frame>72 hours</time_frame>
    <description>AUC for drug concentration in milk</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Milk Expression, Breast</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine liposome</intervention_name>
    <description>blood and milk samples will be obtained from those subjects after TAP block</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients undergoing scheduled C-section delivery
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant women &gt;18 year old, scheduled for elective Cesarean delivery and who desire
             to have a TAP block performed after delivery.

          2. American Society of Anesthesiologists physical status I, II, and III

        Exclusion Criteria:

          1. Patient refusal or inability to cooperate.

          2. Allergy, hypersensitivity, intolerance, or contraindication to liposomal bupivacaine.

          3. Severely impaired renal or hepatic function (eg, serum creatinine level &gt;2 mg/dL
             [176.8 µmol/L], blood urea nitrogen level &gt;50 mg/dL [17.9 mmol/L], serum aspartate
             aminotransferase [AST] level &gt;3 times the upper limit of normal [ULN], or serum
             alanine aminotransferase [ALT] level &gt;3 times the ULN).

          4. Participants at an increased risk for bleeding or with any coagulation disorder
             (defined as platelet count less than 80, 000 × 103/mm3 or international normalized
             ratio greater than 1.5) (all contraindications to TAP block).

          5. Clinically significant medical disease in either the mother or baby that, in the
             opinion of the investigator, would make participation in a clinical study
             inappropriate. This includes any psychiatric or other disease in the mother that would
             constitute a contraindication to participation in the study or cause the mother to be
             unable to comply with the study requirements.

          6. Patient membership in a vulnerable population such as a prisoner, mentally unable to
             provide direct consent etc.

          7. Participant has contraindication to breastfeeding or not planning to breastfeed the
             first 2-3 days after delivery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liposomal bupivacaine</keyword>
  <keyword>TAP block</keyword>
  <keyword>cesarean section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

